Citigroup initiated coverage on Zenas Biopharma with a new price target
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $27.00
Get the next $ZBIO alert in real time by email
Get the next $ZBIO alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ZBIO
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $35.00 | Outperform | Wedbush |
| 2/4/2025 | $19.00 | Outperform | Wolfe Research |
| 12/16/2024 | $30.00 | Buy | H.C. Wainwright |
| 11/5/2024 | $34.00 | Buy | Rodman & Renshaw |
| 10/8/2024 | $45.00 | Buy | Guggenheim |
| 10/8/2024 | $40.00 | Overweight | Morgan Stanley |
| 10/8/2024 | $35.00 | Buy | Jefferies |
| 10/8/2024 | $27.00 | Buy | Citigroup |
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- - Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025- - Out-licensed greater-China anti-IGF-1R Thyroid Eye Disease programs to Zai Lab - WALTHAM, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmac
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management's fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET. A live webcast and archived replay of the Company's presentation can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc. Zenas is a clinical-stage global biopharmaceutica
Wedbush initiated coverage on Zenas Biopharma with a new price target
Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00
Wolfe Research initiated coverage on Zenas Biopharma with a new price target
Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00
H.C. Wainwright initiated coverage on Zenas Biopharma with a new price target
H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00
Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
Chief Executive Officer Moulder Leon O Jr bought $718,100 worth of shares (70,000 units at $10.26), increasing direct ownership by 41% to 241,155 units (SEC Form 4)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
SEC Form 3 filed by new insider Von Moltke Lisa
3 - Zenas BioPharma, Inc. (0001953926) (Issuer)
Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
SEC Form SCHEDULE 13G filed by Zenas BioPharma Inc.
SCHEDULE 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
SEC Form S-8 filed by Zenas BioPharma Inc.
S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)
SEC Form 10-K filed by Zenas BioPharma Inc.
10-K - Zenas BioPharma, Inc. (0001953926) (Filer)
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s
SEC Form SC 13G filed by Zenas BioPharma Inc.
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
SEC Form SC 13G filed by Zenas BioPharma Inc.
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
SEC Form SC 13G filed by Zenas BioPharma Inc.
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)